PD1-PD L1 inhibitor Polaris

CAS No. 2201132-36-5

PD1-PD L1 inhibitor Polaris( —— )

Catalog No. M13510 CAS No. 2201132-36-5

PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PD1-PD L1 inhibitor Polaris
  • Note
    Research use only, not for human use.
  • Brief Description
    PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1.
  • Description
    PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1 interaction (IC50=0.1-10 nM in ELISA assays) with anti-cancer activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2201132-36-5
  • Formula Weight
    834.646
  • Molecular Formula
    C42H46Br2N2O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    (2S,2'S)-1,1'-(((((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(methylene))bis(oxy))bis(3-bromo-4,1-phenylene))bis(methylene))bis(piperidine-2-carboxylic acid)

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • INCB086550

    INCB086550 (PD-1/PD-L1-IN-8) (example 24) is a PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM.

  • Nivolumab

    Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1PD-1PCD-1) with immune checkpoint inhibitory and antineoplastic activities.

  • AUNP-12

    AUNP-12 (Aurigene-012) is a PD-1 inhibitor peptide.